Prosecution Insights
Last updated: April 19, 2026
Application No. 18/565,565

FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME

Non-Final OA §102§112
Filed
Nov 30, 2023
Examiner
JACKSON, SHAWQUIA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Compass Pathfinder Ltd.
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
2y 5m
To Grant
74%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allow Rate
1410 granted / 1810 resolved
+17.9% vs TC avg
Minimal -3% lift
Without
With
+-3.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
29 currently pending
Career history
1839
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
7.1%
-32.9% vs TC avg
§102
19.3%
-20.7% vs TC avg
§112
52.2%
+12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1810 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-5, 8-11, 21, 22, 28, 30-35, 39-42, 48-58 and 60 are currently pending in the instant application. Applicants have amended claims 2-5, 9-11, 21, 22, 28, 30-33, 35, 39, 40, 42, 48-53, 55, 56, 58 and 60 and canceled claims 6, 7, 12-20, 23-27, 29, 36-38, 43-47, 59 and 61 in an amendment filed on November 30, 2023. Claims 1-5, 8-11, 22, 28, 30-33, 49, 50, 52-58 and 60 are rejected, claim 21 is objected and claims 34, 35, 39, 40, 41, 42, 48 and 51 are considered allowable in this Office Action. I. Priority The instant application is a 371 of PCT/US2022/032000, filed on June 2, 2022 which claims benefit of US Provisional Applications 63/195,943, filed on June 2, 2021 and 63/288,313, filed on December 10, 2021. II. Information Disclosure Statement The information disclosure statements (IDS) submitted on November 30, 2023, February 22, 2024 and March 17, 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner. III. Rejections Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless - (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5, 8, 9, 11, 22, 28,30, 31, 32, 49, 50 and 52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by PubChem 67394638 (created November 30, 2012). The instant invention claims PNG media_image1.png 834 771 media_image1.png Greyscale PNG media_image2.png 884 738 media_image2.png Greyscale The PubChem 67394638 reference teaches the compound PNG media_image3.png 244 290 media_image3.png Greyscale wherein R7 is F; R4-R6 are H; R3 is H; Ra1 and Ra2 are H; Rb1 and Rb2 are H; one of R1 and R2 is methyl and the other is cyclopropyl. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above. Claims 1, 9, 11, 22, 30, 31, 33, 49, 50 and 52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2171160-05-5 (entered in STN on January 29, 2018). The instant invention claims PNG media_image1.png 834 771 media_image1.png Greyscale PNG media_image2.png 884 738 media_image2.png Greyscale The RN 2171160-05-5 reference teaches the compound PNG media_image4.png 175 342 media_image4.png Greyscale wherein R6 is F; R4-R5 and R7 are H; R3 is H; Ra1 and Ra2 combine to form a carbonyl; one of R1 and R2 combines with one of Rb1 and Rb2 to form pyrrolidine and the other R1 and R2 is methyl; the other Rb1 and Rb2 is H. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above. Claims 1, 3, 5, 8, 9, 11, 22, 28,30, 31, 32, 49, 50 and 52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Magne, et al. (Advanced Synthesis and Catalysis, 359 (22), and supporting information, 2017, 4036-4042). The instant invention claims PNG media_image1.png 834 771 media_image1.png Greyscale PNG media_image2.png 884 738 media_image2.png Greyscale The Magne, et al. reference teaches the compound PNG media_image5.png 112 219 media_image5.png Greyscale (see compound 1f, page S13) wherein R5 is F; R4, R6 and R7 are H; R3 is H; Ra1 and Ra2 are H; Rb1 and Rb2 are H; one of R1 and R2 is C3 alkenyl and the other is C3 alkynyl. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above. Claims 1-5, 8, 9, 11, 22, 28,30, 31, 49, 50 and 52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 848764-74-9 (entered in STN on April 19, 2005). The instant invention claims PNG media_image1.png 834 771 media_image1.png Greyscale PNG media_image2.png 884 738 media_image2.png Greyscale The RN 848764-74-9 reference teaches the compound PNG media_image6.png 186 412 media_image6.png Greyscale wherein R5 is F; R4, R6, R7 are H; R3 is H; Ra1 and Ra2 are H; Rb1 and Rb2 are H; one of R1 and R2 is methyl and the other is dioxane. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above. Claims 1-5, 8-11, 22, 28,30, 31, 49, 50 and 52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2107983-01-5 (entered in STN on August 3, 2017). The instant invention claims PNG media_image1.png 834 771 media_image1.png Greyscale PNG media_image2.png 884 738 media_image2.png Greyscale The RN 2107983-01-5 reference teaches the compound PNG media_image7.png 175 360 media_image7.png Greyscale wherein R4 is F; R5, R6, R7 are H; R3 is H; Ra1 and Ra2 are H; Rb1 and Rb2 are H; one of R1 and R2 is methyl and the other is methyl substituted with CN. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above. Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 22 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 22 recites the broad recitation R5 which is selected from the group consisting of H, F, Cl, OMe, OH and Me, and the claim also recites “optionally wherein R5 is OMe or F” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Applicants are suggested to amend claim 22 by deleting the narrower language or the broader language to overcome the rejection. Claim 28 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 22 recites the broad recitation L which is selected from the group consisting of PNG media_image8.png 73 226 media_image8.png Greyscale , and the claim also recites “optionally wherein L is PNG media_image9.png 36 82 media_image9.png Greyscale ” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Applicants are suggested to amend claim 28 by deleting the narrower language or the broader language to overcome the rejection. Claims 53-58 and 60 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, the limitation in claim 53 which is drawn to “or at least one compound of any of compounds 1-218” do not clearly define the structure or name of each compound. The examiner must refer to the specification to find the structures of the various compounds being referred in claim 53. A claim referring to the specification is improper except in rare instances and fails to particularly point out the subject matter that applicant regards as the invention. Ex parte Fressola, 27 USPQ 2d 1608 (1993). To overcome the rejection, Applicants need to insert the structures of each ligand disclosed in claim 53. V. Objections Dependent Claim Objections Dependent Claim 21 is objected as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim. VI. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Nov 30, 2023
Application Filed
Feb 04, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600903
DELAYED FLUORESCENCE COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12594265
METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3
2y 5m to grant Granted Apr 07, 2026
Patent 12595231
NOVEL CRYSTALLINE SALT FORMS OF MESEMBRINE
2y 5m to grant Granted Apr 07, 2026
Patent 12590047
METHOD FOR PRODUCING FLUORINE-CONTAINING OLEFIN
2y 5m to grant Granted Mar 31, 2026
Patent 12583818
NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
74%
With Interview (-3.4%)
2y 5m
Median Time to Grant
Low
PTA Risk
Based on 1810 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month